VeriSign Inc. (VRSN) Falls 4.91% for January 04

Equities Staff  |

One of the S&P 500’s big losers for Monday January 04 was VeriSign Inc. (VRSN). The company’s stock fell 4.91% to $83.07 on volume of 1.09 million shares.

The stock opened the day at 85.69 and traded between a low of $82.44 and a high of $86.15. The stock finished the day down $4.29 per share. VeriSign Inc. has an average daily volume of 1.06 million and a total float of 111.51 million shares. The 50-day SMA for VeriSign Inc. is $85.88 and its 200-day SMA is $71.74. The high for the stock over the last 52 weeks is $93.94 and the low is $53.48.

VeriSign Inc is a provider of domain name registry services and internet security, enabling internet navigation for many of the world's recognized domain names and providing protection for websites and enterprises around the world.

VeriSign Inc. is centered in Reston, VA, and has 1,061 employees. Today’s trading day leaves the company with a market cap of $9.26 billionwith a P/E Ratio of 34.3. The company has a P/S ratio of 12.38, P/B ratio of -8.98, and a 22.4.

For a complete fundamental analysis analysis of VeriSign Inc., check out’s Stock Valuation Analysis report for VRSN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor,; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.